Skip to Main Content

Exact Sciences announced Tuesday it had acquired Thrive Earlier Detection, a liquid biopsy company that launched last year with technology from Johns Hopkins University, for $2.15 billion.

The acquisition is yet another boon for the liquid biopsy industry, which has matured in the last five years from “the long-sought holy grail of oncology” to a concept with concrete data behind it. This is the second acquisition this year of a liquid biopsy company developing tests for healthy people; the major DNA sequencing machine maker Illumina bought Grail for $8 billion in cash and stock in September.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!